Bain Capital Life Sciences Investors’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,400,000	Closed	-$32.7M	–	32
2021 Q1	$32.7M	Hold	1,400,000	–	–	1.86%	13
2020 Q4	$40.3M	Hold	1,400,000	–	–	2.53%	12
2020 Q3	$28.4M	Hold	1,400,000	–	–	2.64%	10
2020 Q2	$42.1M	Sell	1,400,000 -803,529	-36%	-$28.9M	4.41%	7
2020 Q1	$69.3M	Sell	2,203,529 -620,000	-22%	-$21.6M	11.71%	4
2019 Q4	$133M	Buy	+2,823,529	New	+$81.5M	19.84%	2

Other funds holding CNST

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

OPU

Omni Partners US Irvine, California $1.95B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's CNST Position: Q2 2021 in Review

Bain Capital Life Sciences Investors sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 1,400,000 shares — an estimated $32.7M sold.

Bain Capital Life Sciences Investors first reported a position in CNST in Q4 2019 and held it in 6 quarters. The position peaked at $133M in Q4 2019. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

Bain Capital Life Sciences Investors reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 1,400,000 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $32.7M.
Bain Capital Life Sciences Investors first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
Bain Capital Life Sciences Investors's Constellation Pharmaceuticals, Inc. position peaked at $133M in Q4 2019.
153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2021, filed 16 Aug 2021.